StreetInsider.com News Articles

Gossamer Bio Inc. (GOSS) PT Raised to $90 at H.C. Wainwright

Mon, 21 Sep 2026 07:35:51 -0400

H.C. Wainwright analyst Patrick Trucchio raised the price target on Gossamer Bio Inc. (NASDAQ: GOSS) to $90.00 (from $2.00) while maintaining a Buy rating.

Form 4 Gossamer Bio, Inc. For: Aug 24 Filed by: Hasnain Faheem

Fri, 18 Sep 2026 12:39:00 -0400

si-local-file:///var/storage/secattach/20260918/27079726.html

Form 4 Gossamer Bio, Inc. For: Aug 24 Filed by: Peterson Caryn

Fri, 18 Sep 2026 12:39:00 -0400

si-local-file:///var/storage/secattach/20260918/27079729.html

Form 4 Gossamer Bio, Inc. For: Aug 24 Filed by: Christian Waage

Fri, 18 Sep 2026 12:39:00 -0400

si-local-file:///var/storage/secattach/20260918/27079740.html

Form 4 Gossamer Bio, Inc. For: Aug 24 Filed by: Smith Robert Paul JR

Fri, 18 Sep 2026 12:39:00 -0400

si-local-file:///var/storage/secattach/20260918/27079744.html

Form 4 Gossamer Bio, Inc. For: Aug 24 Filed by: Giraudo Bryan

Fri, 18 Sep 2026 12:39:00 -0400

si-local-file:///var/storage/secattach/20260918/27079749.html

Form DEF 14A Gossamer Bio, Inc. For: Oct 27

Wed, 16 Sep 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260916/27070717.html

Form 8-K Gossamer Bio, Inc. For: Sep 16

Wed, 16 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260916/27070300.html

Gossamer Bio adds Greg Ciongoli to its board of directors

Wed, 16 Sep 2026 16:01:11 -0400

Gossamer Bio, Inc. (Nasdaq: GOSS) announced the appointment of Greg Ciongoli to its board of directors, effective September 16, 2026. Ciongoli will also serve on the company's Audit Committee, according to a press release.

Ciongoli is the founder and managing partner of Adiumentum Capital Management, a Boston-based investment firm he established in April 2024. Before founding Adiumentum, he was a partner at the Baupost Group, where he worked on public and private equity investments.

He currently serves on the boards of REGENXBIO Inc., Zymeworks, Inc., and Atara Biotherapeutics, Inc. Ciongoli holds an A.B. from Princeton University and an M.B.A. from Harvard Business

Gossamer Bio Appoints Greg Ciongoli to Board of Directors

Wed, 16 Sep 2026 16:01:00 -0400

SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that Greg Ciongoli has been appointed to the Company's Board of Directors, effective September 16, 2026. Mr. Ciongoli will also serve as a member of the Audit Committee.

Mr. Ciongoli has served as the Founder and Managing Partner of Adiumentum Capital Management, a Boston-based investment firm, since April 2024. Prior to Adiumentum, he was a Partner at the Baupost

Gossamer Bio Appoints Greg Ciongoli to Board of Directors

Wed, 16 Sep 2026 16:01:00 -0400

Mr. Ciongoli has served as the Founder and Managing Partner of Adiumentum Capital Management, a Boston-based investment firm, since April 2024. Prior to Adiumentum, he was a Partner at the Baupost

Form 8-K Gossamer Bio, Inc. For: Sep 10

Fri, 11 Sep 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260911/27050880.html

Gossamer Bio completes 1-for-80 reverse stock split on Nasdaq

Fri, 11 Sep 2026 08:00:22 -0400

Gossamer Bio, Inc. (Nasdaq: GOSS) completed a 1-for-80 reverse stock split of its common stock, effective at 11:59 p.m. Eastern Time on September 10, 2026. Shares began trading on a split-adjusted basis on the Nasdaq Global Select Market on September 11, 2026, under the existing ticker symbol "GOSS" with a new CUSIP number of 38341P 201.

Under the terms of the split, every 80 shares of common stock were automatically reclassified and combined into one share. No fractional shares will be issued; instead, holders entitled to a fractional share will receive a rounded-up whole share.

The authorized shares of common stock were

Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split

Fri, 11 Sep 2026 08:00:00 -0400

SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the previously announced 1-for-80 reverse stock split of the Company’s common stock, par value $0.0001 per share, and a proportionate reduction in the number of authorized shares

Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split

Fri, 11 Sep 2026 08:00:00 -0400

H.C. Wainwright Reiterates Buy Rating on Gossamer Bio Inc. (GOSS)

Thu, 27 Aug 2026 07:09:29 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $2.00 price target on Gossamer Bio Inc. (NASDAQ: GOSS).

The analyst commented: "Following receipt of the official pre-NDA Type B meeting minutes announced on July 27, Gossamer remains on track to submit an NDA for seralutinib in pulmonary arterial hypertension (PAH) in September, supported by one adequate and well-controlled trial, the Phase 3 trial (PROSERA), plus confirmatory evidence from the Phase 2 trial (TORREY) and supportive analyses. Critically, the minutes characterize the degree of statistical significance and the magnitude of the PROSERA treatment effect as review issues rather than filing issues,

Form 4 Gossamer Bio, Inc. For: Aug 24 Filed by: Christian Waage

Wed, 26 Aug 2026 18:13:00 -0400

si-local-file:///var/storage/secattach/20260826/26983094.html

Form 4 Gossamer Bio, Inc. For: Aug 24 Filed by: Christian Waage

Wed, 26 Aug 2026 18:13:00 -0400

si-local-file:///var/storage/secattach/20260826/26983094.html

Form 4 Gossamer Bio, Inc. For: Aug 24 Filed by: Peterson Caryn

Wed, 26 Aug 2026 18:12:00 -0400

si-local-file:///var/storage/secattach/20260826/26983091.html

Form 4 Gossamer Bio, Inc. For: Aug 24 Filed by: Peterson Caryn

Wed, 26 Aug 2026 18:12:00 -0400

si-local-file:///var/storage/secattach/20260826/26983091.html

Form 4 Gossamer Bio, Inc. For: Aug 24 Filed by: Smith Robert Paul JR

Wed, 26 Aug 2026 18:11:00 -0400

si-local-file:///var/storage/secattach/20260826/26983089.html

Form 4 Gossamer Bio, Inc. For: Aug 24 Filed by: Smith Robert Paul JR

Wed, 26 Aug 2026 18:11:00 -0400

si-local-file:///var/storage/secattach/20260826/26983089.html

Form 4 Gossamer Bio, Inc. For: Aug 24 Filed by: Giraudo Bryan

Wed, 26 Aug 2026 18:10:00 -0400

si-local-file:///var/storage/secattach/20260826/26983087.html

Form 4 Gossamer Bio, Inc. For: Aug 24 Filed by: Giraudo Bryan

Wed, 26 Aug 2026 18:10:00 -0400

si-local-file:///var/storage/secattach/20260826/26983087.html

Form 4 Gossamer Bio, Inc. For: Aug 24 Filed by: Hasnain Faheem

Wed, 26 Aug 2026 18:08:00 -0400

si-local-file:///var/storage/secattach/20260826/26983084.html